Tyrosine kinase receptor
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
== Function == | == Function == | ||
| - | '''Tyrosine kinase receptor''' or '''high affinity nerve growth factor receptor''' (TRK-A) play an important role in cellular processes like growth, motility, differentiation and metabolism<ref>PMID:29455648</ref>. | + | '''Tyrosine kinase receptor''' or '''high affinity nerve growth factor receptor''' (TRK-A) play an important role in cellular processes like growth, motility, differentiation and metabolism<ref>PMID:29455648</ref>. Nerve growth factor (NGF) is a neutrotrophin which binds with high affinity to TRK. |
== Disease == | == Disease == | ||
| Line 17: | Line 17: | ||
TRK-A contains an extracellular ligand binding domain (LBD), a transmembrane helix and an intracellular region which contains the kinase domain. The kinase domain (PDB code [[4yne]]} contains the tripeptide DFG which flips out in TRK-A inactivated form. The structure of the complex of TRK-A with the phenylpyrrolidine derivative shows the inhibitor forming hydrogen bonds to Met620 and Lys572 residues and π-π interactions of it with Phe617 and Phe 698 <ref>PMID:26005534</ref>. | TRK-A contains an extracellular ligand binding domain (LBD), a transmembrane helix and an intracellular region which contains the kinase domain. The kinase domain (PDB code [[4yne]]} contains the tripeptide DFG which flips out in TRK-A inactivated form. The structure of the complex of TRK-A with the phenylpyrrolidine derivative shows the inhibitor forming hydrogen bonds to Met620 and Lys572 residues and π-π interactions of it with Phe617 and Phe 698 <ref>PMID:26005534</ref>. | ||
| + | |||
| + | The extracellular domain of TRK-A contains 3 Leu-rich regions flanked by 2 Cys-rich regions, 2 immunoglobulin-like domains and the nerve growth factor (NGF) binding domain. The complex between TRK-A and the nerve growth factor (PDB code [[2igf]]} is a 2:2 dimer. The C-terminal immunoglobulin-like domain interacts with the NGF<ref>PMID:17196528</ref>. | ||
</StructureSection> | </StructureSection> | ||
Revision as of 09:05, 30 March 2020
| |||||||||||
3D Structures tyrosine kinase receptor
Updated on 30-March-2020
- Tyrosine kinase receptor or high affinity nerve growth factor receptor; Domains – extracellular 36-382; LBD 285-380; transmembrane 410-447; kinase 498-796
1he7 – hTRK-A LBD domain – human
4crp – hTRK-A LBD domain (mutant) – NMR
2ifg – hTRK-A extracellular domain + b-nerve growth factor
4gt5, 4f0i] – hTRK-A kinase domain
5kvt, 6pl1, 6npt, 6nsp, 6nss, 5wr7, 6d1y, 6d1z, 6pmc, 6iqn, 6pl2, 6pl3, 6pma, 6pmb, 6pme, 5kmj, 5kmk, 5kmm, 5kmn, 5kmo, 4aoj, 4pmm, 4pmp, 4pms, 4pmt, 4yps, 5h3q, 5i8a, 5kmi, 5kml, 6d20, 6dkb, 6dkg, 6dki, 6j5l, 5jfs, 5jfv, 5jfw, 5jfx, 4yne, 6dkw – hTRK-A kinase domain + inhibitor
2n90 – hTRK-A transmembrane domain - NMR
References
- ↑ Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. PMID:29455648 doi:http://dx.doi.org/10.1186/s12943-018-0782-4
- ↑ Cassol CA, Winer D, Liu W, Guo M, Ezzat S, Asa SL. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Mod Pathol. 2014 Aug;27(8):1050-62. doi: 10.1038/modpathol.2013.233. Epub 2014, Jan 3. PMID:24390213 doi:http://dx.doi.org/10.1038/modpathol.2013.233
- ↑ Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett. 2015 Mar 16;6(5):562-7. doi: 10.1021/acsmedchemlett.5b00050., eCollection 2015 May 14. PMID:26005534 doi:http://dx.doi.org/10.1021/acsmedchemlett.5b00050
- ↑ Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. PMID:17196528 doi:10.1016/j.neuron.2006.09.034
